Business Context and Reporting Period
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for cardiorenal conditions, initially uncontrolled or resistant hypertension and chronic kidney disease. The Form 10-Q covers the quarter and six months ended June 30, 2023.
The company has no approved products, has generated no revenue, and remains dependent on capital markets to fund research and development.
Financial Highlights
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11.9 million | $24.2 million |
| General and administrative expense | $3.9 million | $6.5 million |
| Total operating expenses | $15.7 million | $30.7 million |
| Interest and other income, net | $3.6 million | $5.9 million |
| Net loss | $12.1 million | $24.7 million |
| Net loss per share | $0.31 | $0.77 |
| Net cash used in operating activities | Not separately provided | $33.2 million |
As of June 30, 2023, cash and cash equivalents were $101.1 million, current investments were $160.0 million, and noncurrent investments were $21.7 million. Cash, cash equivalents, and investments totaled $282.8 million. Current liabilities were $6.2 million, and stockholders’ equity was $285.0 million. The filing does not disclose a material debt balance.
Operating and net margins are not meaningful because the company has no revenue. The accumulated deficit was $77.6 million.
Material Changes Versus Prior Comparable Period
- Second-quarter research and development expense increased $6.3 million, or approximately 112%, to $11.9 million from $5.6 million, primarily due to the initiation of the pivotal lorundrostat program, higher compensation, and increased clinical supply, manufacturing, and regulatory costs.
- Six-month research and development expense increased $11.8 million, or approximately 95%, to $24.2 million. The increase included a $4.0 million Mitsubishi Tanabe development milestone, higher clinical and preclinical costs, compensation, and clinical supply expenses.
- Second-quarter general and administrative expense increased $3.0 million, or approximately 336%, to $3.9 million, reflecting increased personnel, public-company professional fees, insurance, and other administrative costs.
- Six-month net loss increased $10.7 million to $24.7 million from $14.0 million, despite $5.9 million of interest and other income in 2023.
- Net cash used in operating activities increased to $33.2 million from $12.0 million for the six-month period.
- The company completed its February 2023 IPO, issuing 13.8 million shares at $16.00 per share and receiving approximately $201.4 million of net proceeds. Existing preferred stock converted into common stock, and shares outstanding increased to 40.9 million at June 30, 2023.
- The company invested $218.9 million in marketable securities during the six months, partially offset by $62.5 million of maturities.
Guidance, Outlook, Risks, and Unusual Items
- Advance-HTN, a randomized Phase 2 pivotal hypertension trial targeting up to approximately 300 subjects, was initiated in April 2023. Topline data are expected in the first half of 2024.
- Launch-HTN, a planned Phase 3 hypertension trial targeting up to approximately 1,000 subjects, is expected to begin in the second half of 2023, with topline data expected in mid-2025.
- A Phase 2 chronic kidney disease trial is planned for the second half of 2023, with topline data anticipated between the fourth quarter of 2024 and the first quarter of 2025.
- Management expects operating expenses and losses to increase substantially as clinical development, manufacturing, regulatory, intellectual property, personnel, and public-company costs expand.
- Management believes existing cash, cash equivalents, and investments will fund operations for at least twelve months from the financial statement issuance date, but this estimate is subject to clinical, regulatory, enrollment, manufacturing, and cost uncertainties.
- The company expects to require additional financing and has no committed external source of funds. Future equity financing could dilute stockholders; debt or partnership financing may impose restrictive terms or require surrendering valuable rights.
- The Mitsubishi Tanabe license includes up to $9.0 million of development milestones, up to $165.0 million of commercial milestones across indications, and tiered royalties ranging from the mid-single digits to 10% of net sales. Timing and likelihood of future payments cannot currently be estimated.
- There were no material legal proceedings, no material changes to previously disclosed risk factors, and no material changes in internal control over financial reporting. Disclosure controls were considered effective as of June 30, 2023.
Investor Verification Items
- Verify enrollment, execution, and regulatory progress for the Advance-HTN, Launch-HTN, and planned chronic kidney disease trials against the stated timelines.
- Monitor quarterly cash burn, clinical trial spending, and the projected cash runway relative to the company’s at-least-twelve-month estimate.
- Assess the probability, timing, and potential cost of future Mitsubishi Tanabe milestone and royalty obligations.
- Review future financing activity, including potential equity dilution, debt covenants, or collaboration economics.
- Evaluate clinical efficacy, safety, patient enrollment, and regulatory feedback for lorundrostat, as the company has no approved products or product revenue.